Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.
You may also be interested in...
Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
Though the initial effects were better in the GEMINI I study in ulcerative colitis than in the GEMINI II study in Crohn’s, the effects of the selective integrin antagonist became more evident by week 28 during the maintenance phase of that trial, researchers note in the New England Journal of Medicine.
Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
Though the initial effects were better in the GEMINI I study in ulcerative colitis than in the GEMINI II study in Crohn’s, the effects of the selective integrin antagonist became more evident by week 28 during the maintenance phase of that trial, researchers note in the New England Journal of Medicine.
Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
Though the initial effects were better in the GEMINI I study in ulcerative colitis than in the GEMINI II study in Crohn’s, the effects of the selective integrin antagonist became more evident by week 28 during the maintenance phase of that trial, researchers note in the New England Journal of Medicine.